....I had to double check the shorthand 'n' meaning AND. Had it been NO seminal vessels some of the advice would have caveats.
For those reading this with prostate (likely) contained disease there is emerging information. One study found that those without the certain biomarker had no benefit with long term androgen deprivation therapy, 18-30 months [LATD/LTD], versus those on short term therapy 6 months, [STADT/STDT]. Those with the biomarker revealed an added benefit of disease free progression with LATD versus STADT. It was in the 15% range. It might be noted that the underlying data derived was before the general application of the newest technologies. [Dye enhanced 3T mpMRI, PSMA PETCT scans, (ultrasensitive PSA hallmarks?) and focused spot external beam radiotherapy {e.g. SBRT}] Speculation: The 15% difference may be less and essentially a toss-up for those willing or unwilling to get a marginally lessened progression benefit. This biomarker's discoverer is in search of commercialization opportunities,